Wednesday, Jul 26, 2006
South San Francisco, Calif. -- July 26, 2006 --Genentech, Inc. (NYSE: DNA) today announced the appointment of Gary Harbour, Ph.D. to vice president, Commercial Quality, South San Francisco and the promotion of Robert Andreatta to controller.
Gary Harbour, Ph.D.
Vice President, Commercial Quality, South San Francisco
Gary Harbour joins Genentech as vice president, Commercial Quality, South San Francisco, reporting to Vince Anicetti, vice president, Commercial Quality. In this role, Harbour will be responsible for leading the Quality function in all commercial bulk, filling and packaging operations in South San Francisco.
Harbour joins Genentech from Pfizer Inc., where he was senior director of Global Manufacturing Quality Operations Europe and a member of Pfizer's Quality Leadership Team. Prior, Harbour held various quality and global supply vice-presidential roles with Upjohn and then Pharmacia and served on the board of directors for various international companies.
Harbour holds a Bachelor of Science in chemistry from the University of Utah and a doctorate in medicinal chemistry from the University of Illinois at Urbana.
Robert Andreatta was promoted to controller, an officer position within the company, reporting to John Whiting, vice president, Finance and chief accounting officer. In this role, Andreatta will be responsible for accounting and reporting, financial services, collaborations finance, and tax.
Andreatta joined Genentech in 2003 as director, Collaborations Finance. He has held positions of increasing responsibility, including director, Corporate Accounting and Reporting, and senior director, Corporate Finance and assistant controller.
Prior to his employment with Genentech, Andreatta was chief operating officer and chief financial officer at HopeLink Corporation. Prior to that, he was an audit partner with KPMG.
Andreatta holds a Bachelor of Science in accounting from Santa Clara University.
Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.